Astria Therapeutics

ATXS

市值 US$7.18億

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the “Merger”). The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions. About Astria Therapeutics Astria Therapeutics is a biopharmaceutical company, whose mission i.

I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst's announced acquisition, expecting a 90%+ chance of deal closure by Q1 2026. The investment thesis shifts from clinical catalyst to merger arbitrage, with strong strategic rationale for BCRX to acquire ATXS and minimal regulatory or financial barriers anticipated. Navenibart (STAR-0215) is viewed as a best-in-class prophylaxis agent, and the acquisition offers shareholders a liquidity event, mitigating phase 3 and competitive risks.

Astria Therapeutics, Inc. (ATXS) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.42 per share a year ago.

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. “We believe that the proposed transaction with BioCryst provides the best opportunity to advance navenibart, enabling people with HAE to potentially live free from the limitations of their disease,” said Ji.

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive results from the full enrollment group of 29 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. Conducted across 20 sites in six countries, the trial demonstrated.

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final results from the ALPHA-STAR Phase 1b/2 trial of navenibart in people living with hereditary angioedema (HAE) at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting, taking place November 6-10, 2025 in Orlando, Florida. Aleena Banerji, M.D.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). Under the terms of the proposed transaction, shareholders of Astria will receive $8.55 in cash and 0.59 shares of BioCryst common stock for each share of Astria that they own. KSF is seeking to determ.

ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.

NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK , Oct. 14, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Astria Therapeutics, Inc. (NASDAQ:  ATXS ) related to its sale to BioCryst Pharmaceuticals, Inc. Under the terms of the proposed transaction, Astria shareholders will receive $8.55 in cash per share and 0.59 shares of BioCryst common stock per Astria share.